The global myelofibrosis treatment market size reached US$ 642.4 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 881.2 Million by 2027, exhibiting a growth rate (CAGR) of 5.32% during 2022-2027.
Myelofibrosis is a chronic leukemia disease that affects the blood-forming tissues in the body. It increases the risk of bleeding, which leads to extensive scarring in bone marrow, severe anemia, weakness, and fatigue. It can be diagnosed using physical examination, blood tests, bone marrow tests, imaging tests, and human leukocyte antigen (HLA) typing. At present, various methods of treating myelofibrosis are available, depending on the patients’ symptoms and circumstances. These methods include targeted drug therapy, chemotherapy, surgical interventions, radiation therapy, and stem cell transplantation. In addition, several drugs are being introduced that aid in reducing blood volume and providing relief from different signs and symptoms of the disease.
Myelofibrosis Treatment Market Trends:
Factors like thrombocythemia, polycythemia vera, and exposure to industrial chemicals and high levels of radiation can increase the risk of myelofibrosis. As a result, the rising occurrence of these risk factors among a significant part of the population represents one of the key factors impelling the market growth. Moreover, as primary myelofibrosis is the most diagnosed disease among people of 50 years and above, the growing geriatric population and improving diagnostic modalities are positively influencing the demand for myelofibrosis treatment methods worldwide. Apart from this, increasing sales of new drugs that can assist in relieving chronic signs and symptoms of patients are driving the market. For instance, Janus kinase (JAK) inhibitors can lessen the symptoms of an enlarged spleen, night sweats, itching, and bone pain, while immunomodulators help in the normal functioning of the immune system. Furthermore, the increasing investments in research and development (R&D) activities are anticipated to advance the knowledge of myelofibrosis disease and its treatment options and impel the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global myelofibrosis treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug type, treatment type and end user.
Breakup by Drug Type:
- JAK Inhibitor
Breakup by Treatment Type:
- Blood Transfusion
- Androgen Therapy
- Stem Cell/Bone Marrow Transplantation
Breakup by End User:
- Hospitals and Clinics
- Bone Marrow Transplant Centres
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc. and Novartis AG.
|Base Year of the Analysis
| Historical Period
||Drug Type, Treatment Type, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc. and Novartis AG
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global myelofibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global myelofibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global myelofibrosis treatment market and who are the key players?
- What is the degree of competition in the industry?